Biotech RadarJobs updated

COMPANY

Mineralys Therapeutics

HQ: Radnor, PA source · mineralystx.com ↗ · Mid-Atlantic

Clinical Phase 3

41 open jobs · last seen Oct 23, 2026 · 10 sources

Mineralys Therapeutics develops lorundrostat for uncontrolled and resistant hypertension, with aldosterone as the therapeutic target. Mineralys Therapeutics has completed six late-stage clinical trials of lorundrostat (MLS-101), which it licensed in 2020 from Mitsubishi Tanabe Pharmaceutical Company. From company website Source · checked 2026-10-19

Sources for this description (2)
  • Mineralys Therapeutics develops lorundrostat for uncontrolled and resistant hypertension, with aldosterone as the therapeutic target.
    • “Mineralys has now completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uncontrolled and resistant hypertension.” https://mineralystx.com/about/ (2026-10-19)
  • Mineralys Therapeutics has completed six late-stage clinical trials of lorundrostat (MLS-101), which it licensed in 2020 from Mitsubishi Tanabe Pharmaceutical Company.
    • “Mineralys has now completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uncontrolled and resistant hypertension.” https://mineralystx.com/about/ (2026-10-19)
    • “In 2020, Mineralys licensed lorundrostat (MLS-101) from Mitsubishi Tanabe Pharmaceutical Company (now Tanabe Pharma Corporation), which discovered and developed the compound through phase 1.” https://mineralystx.com/about/ (2026-10-19)

Disease: resistant hypertension

Product: MLS-101

Keywords: Hypertension Obstructive Sleep Apnea Chronic Kidney Disease Renal Hypertension lorundrostat

Profile checked Oct 10, 2026

Since the raise (Jun 3, 2026): 41 of 41 open jobs were first seen after it.

41Open jobs$638.7MRaised (2 yrs)6Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Regional Sales Director - New OrleansUS RemoteOct 21, 2026Oct 22, 2026
Regional Sales Director - Washington D.C.US RemoteOct 21, 2026Oct 22, 2026
Regional Sales Director - Upstate NYUS RemoteOct 21, 2026Oct 22, 2026
Regional Sales Director - St. LouisUS RemoteOct 21, 2026Oct 22, 2026
Regional Sales Director - San FranciscoUS RemoteOct 21, 2026Oct 22, 2026

See all 41 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (41 open jobs at last check). source ↗
  2. Raise Follow-on offering: $150M (total, as published), announced Jun 3, 2026. Source: SEC filing. source ↗
  3. Raise Follow-on offering: $287.5M (total, as published), announced Sep 4, 2025. Source: company release on GlobeNewswire. source ↗
  4. Raise Follow-on offering: $201.2M (total, as published), announced Mar 18, 2025. Source: company release on GlobeNewswire. source ↗
  5. Trial start Phase 2: A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension source ↗
  6. Trial start Phase 2: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria source ↗
  7. Trial start Phase 3: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension source ↗
  8. Trial start Phase 3: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension source ↗
  9. Trial start Phase 2: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen source ↗
  10. Trial start Phase 2: Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension source ↗

Open jobs 41

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Regional Sales Director - New OrleansUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - Washington D.C.US RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - Upstate NYUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - St. LouisUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - San FranciscoUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - RichmondUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - PhoenixUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - Oklahoma CityUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - NorthwestUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - NashvilleUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - MilwaukeeUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - MidwestUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - MemphisUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - Long IslandUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - Little RockUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - KnoxvilleUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - ClevelandUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - CharlotteUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - BirminghamUS RemoteOct 21, 2026Oct 22, 2026Not stated
Regional Sales Director - AustinUS RemoteOct 21, 2026Oct 22, 2026Not stated
National Sales Director, CentralUS RemoteOct 21, 2026Oct 22, 2026Not stated
HR Technology & Analytics SpecialistUS Remote Oct 19, 2026Oct 20, 2026Not stated
Senior Medical Science Liaisons (MSL) - Cardiovascular, ArizonaUS RemoteOct 15, 2026Oct 16, 2026Not stated
Senior Medical Science Liaisons (MSL) - Cardiovascular, FloridaUS RemoteOct 15, 2026Oct 16, 2026Not stated
National Sales Director, WestUS RemoteOct 13, 2026Oct 22, 2026Not stated
Director, Legal (Commercial and Medical Review)US Remote Oct 13, 2026Oct 14, 2026Senior
Director, Commercial Strategic SourcingUS Remote Oct 12, 2026Oct 12, 2026Senior
Manager, Commercial AccountingUS Remote Oct 1, 2026Oct 9, 2026Senior
Senior Director, Analytical SciencesUS Remote Sep 30, 2026Oct 9, 2026Senior
Senior Director, Commercial Supply ChainUS Remote Sep 30, 2026Oct 9, 2026Senior
Sr. Manager, Compliance OperationsUS Remote Sep 22, 2026Oct 9, 2026Senior
Senior Vice President, Regulatory AffairsUS Remote Sep 11, 2026Oct 9, 2026Executive
Territory Manager - Washington, D.C.US RemoteJul 10, 2026Oct 9, 2026Mid
Territory Manager - Oklahoma City, OKUS RemoteJul 10, 2026Oct 20, 2026Not stated
Territory Manager - New York, NYUS RemoteJul 10, 2026Oct 9, 2026Mid
Territory Manager - Minneapolis, MNUS RemoteJul 10, 2026Oct 17, 2026Not stated
Territory Manager - Columbus, OHUS RemoteJul 10, 2026Oct 9, 2026Mid
Territory Manager - Cleveland, TNUS RemoteJul 10, 2026Oct 15, 2026Mid
Director, ComplianceUS Remote Jun 29, 2026Oct 9, 2026Senior
Regional Sales Director - AtlantaUS RemoteMay 29, 2026Oct 12, 2026Senior
Executive Director, Clinical DevelopmentUS RemoteApr 21, 2026Oct 9, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $638.7M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT05968430Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionPhase 3Active, not recruitingJul 14, 2023Dec 30, 2025 (actual)
NCT06785454A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionPhase 2CompletedFeb 28, 2025Dec 17, 2025 (actual)
NCT06150924Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaPhase 2CompletedDec 14, 2023Feb 27, 2025 (actual)
NCT06153693Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionPhase 3CompletedNov 22, 2023Dec 10, 2024 (actual)
NCT05769608A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenPhase 2CompletedMar 13, 2023Jan 15, 2025 (actual)
NCT05001945Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled HypertensionPhase 2CompletedJul 1, 2021Sep 7, 2022 (actual)

Connect

See your connections at Mineralys Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback